Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

ClinicalTrials.gov ID: NCT05285891

Public ClinicalTrials.gov record NCT05285891. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)

Study identification

NCT ID: NCT05285891
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 123 participants

Conditions and interventions

Conditions

Multiple Sclerosis

Interventions

Ocrelizumab Drug
Placebo for Ocrelizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 11, 2023
Primary completion: Apr 30, 2030
Completion: Oct 31, 2030
Last update posted: Apr 15, 2026

2023 – 2030

United States locations

U.S. sites: 12
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
Yale School of Medicine	New Haven	Connecticut	06510	Recruiting
MedStar Georgetown University Hospital	Washington D.C.	District of Columbia	20007	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
University of Massachusetts Memorial Medical Center	Worcester	Massachusetts	01655	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10007	Recruiting
University of Rochester Medical Center	Rochester	New York	14627	Recruiting
Oklahoma Medical Research Foundation	Oklahoma City	Oklahoma	73104	Recruiting
University of Pennsylvania, Perelman School of Medicine	Philadelphia	Pennsylvania	19104	Recruiting
University of Texas Southwestern Medical Center	Dallas	Texas	75390	Recruiting
The University of Texas Health Science Center at Houston, McGovern Medical School	Houston	Texas	77030	Recruiting
Virginia Commonwealth University School of Medicine	Richmond	Virginia	23298	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05285891, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 15, 2026 · Synced Apr 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05285891 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →